Protein bioconjugation: Achieving selectivity and purity without protein engineering — ASN Events
  1. Schedule
  2. Session Twelve - Poster Session D including Happy Hour & Trade Display
  3. Protein bioconjugation: Achieving selectivity and purity without protein engineering

Protein bioconjugation: Achieving selectivity and purity without protein engineering (#403)

Judith Scoble 1
  1. CSIRO, Parkville, VIC, Australia

The therapeutic properties of a bioconjugate are highly dependent on the site of attachment of the small molecule (in antibody-drug conjugates such as Trastuzumab-DM1 (Junutula 2010)) or polymer (such as for improving the circulatory half-life and in vivo availability of interferon-beta-1b (Basu 2006)). As an alternative to engineering a non-native amino acid sequence, site-specific bioconjugation can be achieved by careful optimisation of the conjugation and purification conditions.

  1. Basu, A. et al. (2006). Bioconjugate Chemistry 17(3): 618-630.
  2. Junutula, J. R. et al. (2010). Clinical Cancer Research 16(19): 4769-4778.